A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function - Wikidata - wikimedia - TriplyDB

A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function

A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function

http://www.wikidata.org/entity/Q33224746

about

Systematic analysis of off-target effects in an RNAi screen reveals microRNAs affecting sensitivity to TRAIL-induced apoptosis Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity Identification of an antiapoptotic protein complex at death receptors F-box protein FBXL19-mediated ubiquitination and degradation of the receptor for IL-33 limits pulmonary inflammation Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation Small-molecule inhibitors of the Myc oncoprotein Drugging the addict: non-oncogene addiction as a target for cancer therapy A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions.ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells.c-FLIPL enhances anti-apoptotic Akt functions by modulation of Gsk3β activity.Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3 The TRAIL of oncogenes to apoptosis.ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins.Small interfering RNA-based molecular therapy of cancers RNA interference screening for the discovery of oncology targets.Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways.mTOR-independent translational control of the extrinsic cell death pathway by RalA.Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis.Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion.The ins and outs of MYC regulation by posttranslational mechanisms.hnRNPK inhibits GSK3β Ser9 phosphorylation, thereby stabilizing c-FLIP and contributes to TRAIL resistance in H1299 lung adenocarcinoma cells.Targeting MYC in cancer therapy: RNA processing offers new opportunities.Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.Target validation to biomarker development: focus on RNA interference.SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening.The multifaceted role of MTDH/AEG-1 in cancer progression Modulation of glycogen synthase kinase-3β following TRAIL combinatorial treatment in cancer cells.Exploration of synthetic lethal interactions as cancer drug targets.Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.Current views on inducing synthetic lethal RNAi responses in the treatment of cancer.

P2860

Q21267232-315C20E5-F76D-4F8A-877D-9BA4764F1BE7 Q24307490-FAA9DD87-D579-4F32-88EE-3B3A3C8E3599 Q24321594-005267CE-B37E-47AF-A606-EE13B2CE77D6 Q24337221-467DBD35-D46F-4EA0-8699-6B8594338558 Q24655658-42013FC0-B696-4270-9622-ED58423F3417 Q27025648-0928FC90-5E6E-42CF-8EBA-1B7CE80FA465 Q28079559-DDC5E84A-ACC5-4A65-AB64-DF5AC380EEF0 Q28255073-81EF3507-92B0-4A7E-B671-C39C6B44E189 Q28586033-3E82119B-05DE-45F8-A8B1-8C65170EE5BC Q28729017-D9E7678B-44C2-4871-A8D5-E617A8B31AA3 Q29617043-D37AE1DA-C8C2-44D8-AF26-DCAF7D042C31 Q33258367-D18B3724-F03D-4844-990A-4574C184D5CE Q33528959-9762DA74-F77A-41B7-9A59-CE8271932AAF Q33578581-64B1DAD9-C2C6-48BF-86B3-4A374D507B63 Q33589810-7BAA3DFB-3032-4BE8-9DC4-9BAD04B37CBD Q33626022-BE74C3B4-FB1E-4C13-9EEB-A56CC03BF94C Q33710200-6479CAE0-C0A2-438B-ABBB-5B001A2C0B40 Q33925043-3522CD41-0830-4475-87DD-98EA6BF5FA8B Q34005003-FEBA31CB-EBA6-4519-B48C-C8FFC8A79C3C Q34354511-75891806-1FD2-4A75-B838-6B048977412C Q34496536-826A9B0B-2224-4BD5-A35F-5568B9CAC2E1 Q34552948-F4F10DF2-4858-4252-844B-1587085D704C Q34995323-75329E19-2216-4CCD-B736-FF3C732A8B2D Q35059927-5C7F69D0-135D-4F09-9F38-82EA7DCF7874 Q35103813-97079FC5-A02F-49FB-B863-2B415CC6DED1 Q35131738-0F91D83D-8CEC-4584-A299-EC345427A608 Q35941142-7B1BF326-6950-4A0C-836D-BEB52379095D Q36140644-7B5649A7-3FF5-4FB5-AA56-553F766F05A1 Q36599161-5B60390D-A67E-4C9E-A1FD-E0D9206D9043 Q36681641-FE1659F8-2CF5-48D4-8D9D-3403536E5BE0 Q36762189-C87DB89F-5184-461F-AA3D-197D87CEFB66 Q36804432-ACBD2399-7EEF-4FB6-BCBB-CB875027BC9C Q37141990-97445E9D-8D84-4F15-B005-741D24590EFC Q37188977-6D1622B5-6BC4-4BD9-8F7E-BFD1E38EE1F4 Q37574031-EDF775AD-66AB-4D68-9501-D3D216E6BD75 Q37590524-C2BE2933-B026-4064-B7B2-2670B613BCEF Q37687091-54DC23D5-AED0-4916-97BA-4413ADCC0C18 Q37818230-E9E611D5-0746-4C19-97BF-AE7E826EE41A Q38609949-BEEE22E7-7BC9-4101-A7D4-859817D54A27 Q38656763-7305BDB4-31E0-49ED-8055-0BE7EA237B28

P2860

A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function

http://www.wikidata.org/entity/Q33224746

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

A TRAIL receptor-dependent syn ...... GSK3beta/FBW7 loss of function

@ast

A TRAIL receptor-dependent syn ...... GSK3beta/FBW7 loss of function

@en

type

label

A TRAIL receptor-dependent syn ...... GSK3beta/FBW7 loss of function

@ast

A TRAIL receptor-dependent syn ...... GSK3beta/FBW7 loss of function

@en

prefLabel

A TRAIL receptor-dependent syn ...... GSK3beta/FBW7 loss of function

@ast

A TRAIL receptor-dependent syn ...... GSK3beta/FBW7 loss of function

@en

P1433

Q33224746-F0A4E9AF-0678-4035-9CDD-1F2E9161739D

P1476

Q33224746-63DC951E-D92F-4DEC-850D-1B8368275AED

P2093

Q33224746-2162809F-CE09-42C4-ACF5-C3005C954278

Q33224746-28EBD33B-4A0E-4A66-A487-E2634C5BB896

Q33224746-AB8DB6A1-24AA-499E-A699-19C493CECE88

Q33224746-BE6D3FE2-732E-478B-932F-A4DF7690F169

Q33224746-C48EFB10-4632-4716-BC7D-7AD8A22960C3

P2860

Q33224746-008FD9DF-D908-422A-AD1F-918B68A94D3E

Q33224746-048D033F-7266-4EC0-94B2-E7CD61BAECF4

Q33224746-07FE562B-1A05-424E-AE95-90AD0E76934D

Q33224746-09A6453E-4283-4A8C-8101-D7F02F99A5EB

Q33224746-15F194AD-1E1B-4320-B2F2-8CD2A7E1EC99

Q33224746-171AA234-D9A2-4918-AA0F-E97CE815325E

Q33224746-195C3007-4EB2-4108-9024-4DB9B6715517

Q33224746-1CEE4E43-971E-44FF-BC7C-5A7C81E1ACCA

Q33224746-2553880D-ED90-4B13-A5EB-FC883504236C

Q33224746-330C706B-030B-4CA8-B78D-39AC4441ACF9

P304

Q33224746-52B73DAB-7DBF-4461-A04C-1C3B85E06E45

P31

Q33224746-93F62E1A-C714-43D1-85EC-4F982368D3BE

P356

Q33224746-AA1D8E8E-BC34-4324-A57A-9E6C7E544C31

P407

Q33224746-598A5F77-7994-4F42-9AA5-C2513B3CB00F

P433

Q33224746-40E971F8-7D34-4420-8746-4EBE94431574

P478

Q33224746-E5591E3C-1A97-4F5D-ADB3-CBB471FB8E04

P577

Q33224746-751BDE69-1ADB-45FB-8722-2EBC1CE6F78F

P5875

Q33224746-A12FD4B1-B7C3-4CD7-AEB9-84D6116F5573

P698

Q33224746-1A3AB8A2-5716-4184-8598-D671DFE1E1EF

P932

Q33224746-31776E5D-F080-4FCA-851F-F6621E6D058A

P356

PNAS.0505114102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

A TRAIL receptor-dependent syn ...... GSK3beta/FBW7 loss of function

@en

P2093

Kim C Quon

http://www.w3.org/2001/XMLSchema#string

Marc Nasoff

http://www.w3.org/2001/XMLSchema#string

Quinn L Deveraux

http://www.w3.org/2001/XMLSchema#string

Sabine Rottmann

http://www.w3.org/2001/XMLSchema#string

Yan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7

BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets

Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase

GSK-3-selective inhibitors derived from Tyrian purple indirubins

Function and regulation of the transcription factors of the Myc/Max/Mad network

Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB

c-MYC: more than just a matter of life and death

Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation

Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase

P304

15195-15200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0505114102

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7555858

http://www.w3.org/2001/XMLSchema#string

P698

16210249

http://www.w3.org/2001/XMLSchema#string

P932

1257707

http://www.w3.org/2001/XMLSchema#string